Thromboembolic Risks, Ischemic Risks, Cardiac Arrest, and Sudden Deaths

Treatment with ANDEXXA has been associated with serious and life-threatening adverse events, including: 

• Arterial and venous thromboembolic events
• Ischemic events, including myocardial infarction and ischemic stroke
• Cardiac arrest
• Sudden deaths

Monitor for thromboembolic events and initiate anticoagulation when medically appropriate. Monitor for symptoms and signs that precede cardiac arrest and provide treatment as needed.